Genesis R&D Extends Use of MorphoSys' HuCAL Antibodies for Autoimmune Rx Development | GenomeWeb
NEW YORK (GenomeWeb News) — MorphoSys today said Genesis Research and Development will continue using HuCAL-based antibodies in its drug-development research.
 
New Zealand-based Genesis will use the antibodies, developed by MorphoSys’ AbD Serotec segment, against the target molecule FGFR5 for validations and pre-clinical studies for its Zyrogen drug, which is being studied for certain autoimmune diseases, according to Genesis’ website.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.